Business description: Alliance Pharma plc
Number of employees: 290
Sales by Activity: Alliance Pharma plc
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Consumer Healthcare | 85.34M | 115M | 121M | 134M | 129M |
Prescription Medicines | 44.46M | 47.83M | 46.79M | 46.35M | 49.6M |
Geographical breakdown of sales: Alliance Pharma plc
Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|---|
Europe, Middle East and Africa (EMEA) | 93.77M | 89.19M | 78.92M | 79.2M | 83.42M |
Asia Pacific and China (APAC) | 29.31M | 48.03M | 59.19M | 72.42M | 65.93M |
Americas (AMER) | 6.72M | 25.99M | 29.31M | 29.06M | 29.49M |
Executive Committee: Alliance Pharma plc
Manager | Title | Age | Since |
---|---|---|---|
Andrew Franklin
DFI | Director of Finance/CFO | 59 | 27/09/2015 |
Cora McCallum
IRC | Investor Relations Contact | - | 31/12/2021 |
Julie Skinner
HRO | Human Resources Officer | - | 31/10/2023 |
General Counsel | - | 31/12/2016 |
Composition of the Board of Directors: Alliance Pharma plc
Director | Title | Age | Since |
---|---|---|---|
Andrew Franklin
BRD | Director/Board Member | 59 | 27/09/2015 |
Richard Jones
BRD | Director/Board Member | 59 | 31/12/2018 |
Director/Board Member | 47 | 30/11/2021 | |
Director/Board Member | 56 | 31/01/2023 | |
Director/Board Member | 59 | 05/11/2023 | |
Richard McKenzie
BRD | Director/Board Member | 53 | 05/11/2023 |
Camillo Pane
CHM | Chairman | 54 | 18/02/2024 |
Company details: Alliance Pharma plc
Alliance Pharma Plc
Avonbridge House Bath Road
SN15 2BB, Chippenham
+44 12 4946 6966
http://www.alliancepharma.co.uk
Group companies: Alliance Pharma plc
Name | Category and Sector |
---|---|
Alliance Pharmaceuticals Ltd. (United Kingdom)
![]() Alliance Pharmaceuticals Ltd. (United Kingdom) Pharmaceuticals: MajorHealth Technology Part of DBAY Advisors Ltd., Alliance Pharmaceuticals Ltd. is a British company that manufactures pharmaceutical products. The company is based in Chippenham, UK. The company was founded in 1996 by John Dawson. Peter Jonathan Butterfield has been the CEO of the company since 2010. |
Pharmaceuticals: Major
|
Generic Pharmaceuticals
Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
---|---|---|---|---|---|---|
-0.58% | +1.29% | +6.23% | +91.84% | 47.18B | ||
+1.85% | +2.53% | +33.02% | - | 24.65B | ||
-1.20% | -1.63% | -10.16% | +33.84% | 23.41B | ||
-0.01% | -0.18% | -1.62% | +53.23% | 13.9B | ||
-0.79% | -0.47% | -17.77% | +172.14% | 11.39B | ||
+2.35% | +20.86% | +91.35% | +113.84% | 8.45B | ||
-0.05% | +2.04% | +57.46% | +483.43% | 7.29B | ||
0.00% | +0.25% | +34.01% | +100.60% | 7.09B | ||
-.--% | +0.14% | - | - | 6.79B | ||
Average | +0.17% | +2.58% | +24.07% | +149.85% | 16.68B | |
Weighted average by Cap. | +0.00% | +1.72% | +14.49% | +109.73% |